Table 1.
Site distribution of GeneXpert instruments by epidemiological setting and facility level (n = 33).
Fig 1.
Xpert testing strategies and MTB detection.
Table 2.
Detection of MTB by Xpert in 23 sites using Xpert as first test.
Table 3.
Detection of MTB in 7 sites using Xpert as first test in high risk groups.
Table 4.
Detection of MTB in 3 sites using Xpert as first test in high risk groups and as add-on test to microscopy for smear negative presumed TB.
Table 5.
Detection of rifampicin resistance by Xpert according to MDR-TB prevalence.
Table 6.
Results of Xpert compared to smear microscopy.
Table 7.
Relative gain by project for Xpert used as add-on test.
Table 8.
Detection of MTB by Xpert compared to MGIT culture in smear-negative samples.
Table 9.
Inconclusive Xpert results by implementation phase and cartridge version.
Table 10.
Quantitative results from the lessons learned questionnaire (n = 28).